Chronic Kidney Disease Drugs Market Size, Share & Industry Analysis, By Drug Class (SGLT2 Inhibitors, ACE Inhibitors, Angiotensin II Receptor Blockers, Direct Renin Inhibitors, Mineralocorticoid Receptor Antagonists, Endothelin Receptor Antagonists, & Others), By Stage (Stage 1, Stage 2, Stage 3a, Stage 3b, Stage 4, & Others), By Disease Indication (Diabetic Kidney Disease, Hypertensive Nephropathy / Nephrosclerosis, Polycystic Kidney Disease, Chronic Tubulointerstitial Nephritis, & Others), By Route of Administration, By Distribution Channel, and Regional Forecast, 2026-2034

Last Updated: March 17, 2026 | Format: PDF | Report ID: FBI115768

We will customize the report to meet your research goals, helping you gain a competitive edge, and make informed decisions.

Schedule a 30 minutes session to understand our consulting capabilities – SCHEDULE NOW

Table of Content

Introduction
1. Research Scope
2. Market Segmentation
3. Research Methodology
4. Definitions and Assumptions
Executive Summary
Market Dynamics
1. Market Drivers
2. Market Restraints
3. Market Opportunities
4. Market Trends
Key Insights
1. Prevalence of Key Diseases, By Key Countries/Regions, 2025
2. Pipeline Analysis, By Key Players
3. Reimbursement Scenario, By Key Countries/Regions
4. Regulatory Scenario, By Key Countries/Regions
5. New Product Launches, By Key Players
6. Key Industry Developments (Mergers, Acquisitions, Partnerships, and Others)
Global Chronic Kidney Disease Drugs Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Drug Class
  1. SGLT2 Inhibitors
  2. ACE Inhibitors
  3. Angiotensin II Receptor Blockers (ARBs)
  4. Direct Renin Inhibitors
  5. Mineralocorticoid Receptor Antagonists (MRAs)
  6. Endothelin Receptor Antagonists (ERAs)
  7. Immunosuppressants
  8. Corticosteroids
  9. Complement inhibitors
  10. Others
2. Market Analysis, Insights and Forecast – By Stage
  1. Stage 1
  2. Stage 2
  3. Stage 3a
  4. Stage 3b
  5. Stage 4
  6. Stage 5 (Non-Dialysis)
  7. Others
3. Market Analysis, Insights and Forecast – By Disease Indication
  1. Diabetic Kidney Disease (DKD)
  2. Hypertensive Nephropathy / Nephrosclerosis
  3. Glomerular Diseases
  4. Polycystic Kidney Disease (PKD)
  5. Chronic Tubulointerstitial Nephritis
  6. Obstructive Uropathy–related CKD
  7. Systemic Autoimmune–associated CKD
  8. Infectious/Inflammatory–associated CKD
  9. Congenital/Structural Kidney Disorders (non-PKD)
  10. Others
4. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
5. Market Analysis, Insights and Forecast – By Age Group
  1. Pediatrics
  2. Adults
6. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Drug Stores & Retail Pharmacies
  3. Online Pharmacies
7. Market Analysis, Insights and Forecast – Region
  1. North America
  2. Europe
  3. Asia Pacific
  4. Latin America
  5. Middle East & Africa
North America Chronic Kidney Disease Drugs Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Drug Class
  1. SGLT2 Inhibitors
  2. ACE Inhibitors
  3. Angiotensin II Receptor Blockers (ARBs)
  4. Direct Renin Inhibitors
  5. Mineralocorticoid Receptor Antagonists (MRAs)
  6. Endothelin Receptor Antagonists (ERAs)
  7. Immunosuppressants
  8. Corticosteroids
  9. Complement inhibitors
  10. Others
2. Market Analysis, Insights and Forecast – By Stage
  1. Stage 1
  2. Stage 2
  3. Stage 3a
  4. Stage 3b
  5. Stage 4
  6. Stage 5 (Non-Dialysis)
  7. Others
3. Market Analysis, Insights and Forecast – By Disease Indication
  1. Diabetic Kidney Disease (DKD)
  2. Hypertensive Nephropathy / Nephrosclerosis
  3. Glomerular Diseases
  4. Polycystic Kidney Disease (PKD)
  5. Chronic Tubulointerstitial Nephritis
  6. Obstructive Uropathy–related CKD
  7. Systemic Autoimmune–associated CKD
  8. Infectious/Inflammatory–associated CKD
  9. Congenital/Structural Kidney Disorders (non-PKD)
  10. Others
4. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
5. Market Analysis, Insights and Forecast – By Age Group
  1. Pediatrics
  2. Adults
6. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Drug Stores & Retail Pharmacies
  3. Online Pharmacies
7. Market Analysis, Insights and Forecast – By Country
  1. U.S.
  2. Canada
Europe Chronic Kidney Disease Drugs Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Drug Class
  1. SGLT2 Inhibitors
  2. ACE Inhibitors
  3. Angiotensin II Receptor Blockers (ARBs)
  4. Direct Renin Inhibitors
  5. Mineralocorticoid Receptor Antagonists (MRAs)
  6. Endothelin Receptor Antagonists (ERAs)
  7. Immunosuppressants
  8. Corticosteroids
  9. Complement inhibitors
  10. Others
2. Market Analysis, Insights and Forecast – By Stage
  1. Stage 1
  2. Stage 2
  3. Stage 3a
  4. Stage 3b
  5. Stage 4
  6. Stage 5 (Non-Dialysis)
  7. Others
3. Market Analysis, Insights and Forecast – By Disease Indication
  1. Diabetic Kidney Disease (DKD)
  2. Hypertensive Nephropathy / Nephrosclerosis
  3. Glomerular Diseases
  4. Polycystic Kidney Disease (PKD)
  5. Chronic Tubulointerstitial Nephritis
  6. Obstructive Uropathy–related CKD
  7. Systemic Autoimmune–associated CKD
  8. Infectious/Inflammatory–associated CKD
  9. Congenital/Structural Kidney Disorders (non-PKD)
  10. Others
4. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
5. Market Analysis, Insights and Forecast – By Age Group
  1. Pediatrics
  2. Adults
6. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Drug Stores & Retail Pharmacies
  3. Online Pharmacies
7. Market Analysis, Insights and Forecast – By Country/ Sub-Region
  1. U.K.
  2. Germany
  3. France
  4. Italy
  5. Spain
  6. Scandinavia
  7. Rest of Europe
Asia Pacific Chronic Kidney Disease Drugs Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Drug Class
  1. SGLT2 Inhibitors
  2. ACE Inhibitors
  3. Angiotensin II Receptor Blockers (ARBs)
  4. Direct Renin Inhibitors
  5. Mineralocorticoid Receptor Antagonists (MRAs)
  6. Endothelin Receptor Antagonists (ERAs)
  7. Immunosuppressants
  8. Corticosteroids
  9. Complement inhibitors
  10. Others
2. Market Analysis, Insights and Forecast – By Stage
  1. Stage 1
  2. Stage 2
  3. Stage 3a
  4. Stage 3b
  5. Stage 4
  6. Stage 5 (Non-Dialysis)
  7. Others
3. Market Analysis, Insights and Forecast – By Disease Indication
  1. Diabetic Kidney Disease (DKD)
  2. Hypertensive Nephropathy / Nephrosclerosis
  3. Glomerular Diseases
  4. Polycystic Kidney Disease (PKD)
  5. Chronic Tubulointerstitial Nephritis
  6. Obstructive Uropathy–related CKD
  7. Systemic Autoimmune–associated CKD
  8. Infectious/Inflammatory–associated CKD
  9. Congenital/Structural Kidney Disorders (non-PKD)
  10. Others
4. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
5. Market Analysis, Insights and Forecast – By Age Group
  1. Pediatrics
  2. Adults
6. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Drug Stores & Retail Pharmacies
  3. Online Pharmacies
7. Market Analysis, Insights and Forecast – By Country/ Sub-Region
  1. China
  2. Japan
  3. India
  4. Australia
  5. Southeast Asia
  6. Rest of Asia Pacific
Latin America Chronic Kidney Disease Drugs Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Drug Class
  1. SGLT2 Inhibitors
  2. ACE Inhibitors
  3. Angiotensin II Receptor Blockers (ARBs)
  4. Direct Renin Inhibitors
  5. Mineralocorticoid Receptor Antagonists (MRAs)
  6. Endothelin Receptor Antagonists (ERAs)
  7. Immunosuppressants
  8. Corticosteroids
  9. Complement inhibitors
  10. Others
2. Market Analysis, Insights and Forecast – By Stage
  1. Stage 1
  2. Stage 2
  3. Stage 3a
  4. Stage 3b
  5. Stage 4
  6. Stage 5 (Non-Dialysis)
  7. Others
3. Market Analysis, Insights and Forecast – By Disease Indication
  1. Diabetic Kidney Disease (DKD)
  2. Hypertensive Nephropathy / Nephrosclerosis
  3. Glomerular Diseases
  4. Polycystic Kidney Disease (PKD)
  5. Chronic Tubulointerstitial Nephritis
  6. Obstructive Uropathy–related CKD
  7. Systemic Autoimmune–associated CKD
  8. Infectious/Inflammatory–associated CKD
  9. Congenital/Structural Kidney Disorders (non-PKD)
  10. Others
4. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
5. Market Analysis, Insights and Forecast – By Age Group
  1. Pediatrics
  2. Adults
6. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Drug Stores & Retail Pharmacies
  3. Online Pharmacies
7. Market Analysis, Insights and Forecast – By Country/ Sub-Region
  1. Brazil
  2. Mexico
  3. Rest of Latin America
Middle East & Africa Chronic Kidney Disease Drugs Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Drug Class
  1. SGLT2 Inhibitors
  2. ACE Inhibitors
  3. Angiotensin II Receptor Blockers (ARBs)
  4. Direct Renin Inhibitors
  5. Mineralocorticoid Receptor Antagonists (MRAs)
  6. Endothelin Receptor Antagonists (ERAs)
  7. Immunosuppressants
  8. Corticosteroids
  9. Complement inhibitors
  10. Others
2. Market Analysis, Insights and Forecast – By Stage
  1. Stage 1
  2. Stage 2
  3. Stage 3a
  4. Stage 3b
  5. Stage 4
  6. Stage 5 (Non-Dialysis)
  7. Others
3. Market Analysis, Insights and Forecast – By Disease Indication
  1. Diabetic Kidney Disease (DKD)
  2. Hypertensive Nephropathy / Nephrosclerosis
  3. Glomerular Diseases
  4. Polycystic Kidney Disease (PKD)
  5. Chronic Tubulointerstitial Nephritis
  6. Obstructive Uropathy–related CKD
  7. Systemic Autoimmune–associated CKD
  8. Infectious/Inflammatory–associated CKD
  9. Congenital/Structural Kidney Disorders (non-PKD)
  10. Others
4. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
5. Market Analysis, Insights and Forecast – By Age Group
  1. Pediatrics
  2. Adults
6. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Drug Stores & Retail Pharmacies
  3. Online Pharmacies
7. Market Analysis, Insights and Forecast – By Country/ Sub-Region
  1. GCC
  2. South Africa
  3. Rest of the Middle East & Africa
Competitive Analysis
1. Global Market Share Analysis (2025)
2. Company Profiles (Overview, Products & Services, SWOT analysis, Recent developments, strategies, financials (based on availability)
  1. AstraZeneca
  2. Bayer AG
  3. Boehringer Ingelheim Pharmaceuticals, Inc.
  4. Eli Lilly and Company
  5. Novartis AG
  6. Calliditas Therapeutics AB
  7. Otsuka Pharmaceuticals Inc.
  8. GSK plc
  9. Amgen Inc.
  10. Sanofi

Introduction
1. Research Scope
2. Market Segmentation
3. Research Methodology
4. Definitions and Assumptions
Executive Summary
Market Dynamics
1. Market Drivers
2. Market Restraints
3. Market Opportunities
4. Market Trends
Key Insights
1. Prevalence of Key Diseases, By Key Countries/Regions, 2025
2. Pipeline Analysis, By Key Players
3. Reimbursement Scenario, By Key Countries/Regions
4. Regulatory Scenario, By Key Countries/Regions
5. New Product Launches, By Key Players
6. Key Industry Developments (Mergers, Acquisitions, Partnerships, and Others)
Global Chronic Kidney Disease Drugs Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Drug Class
  1. SGLT2 Inhibitors
  2. ACE Inhibitors
  3. Angiotensin II Receptor Blockers (ARBs)
  4. Direct Renin Inhibitors
  5. Mineralocorticoid Receptor Antagonists (MRAs)
  6. Endothelin Receptor Antagonists (ERAs)
  7. Immunosuppressants
  8. Corticosteroids
  9. Complement inhibitors
  10. Others
2. Market Analysis, Insights and Forecast – By Stage
  1. Stage 1
  2. Stage 2
  3. Stage 3a
  4. Stage 3b
  5. Stage 4
  6. Stage 5 (Non-Dialysis)
  7. Others
3. Market Analysis, Insights and Forecast – By Disease Indication
  1. Diabetic Kidney Disease (DKD)
  2. Hypertensive Nephropathy / Nephrosclerosis
  3. Glomerular Diseases
  4. Polycystic Kidney Disease (PKD)
  5. Chronic Tubulointerstitial Nephritis
  6. Obstructive Uropathy–related CKD
  7. Systemic Autoimmune–associated CKD
  8. Infectious/Inflammatory–associated CKD
  9. Congenital/Structural Kidney Disorders (non-PKD)
  10. Others
4. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
5. Market Analysis, Insights and Forecast – By Age Group
  1. Pediatrics
  2. Adults
6. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Drug Stores & Retail Pharmacies
  3. Online Pharmacies
7. Market Analysis, Insights and Forecast – Region
  1. North America
  2. Europe
  3. Asia Pacific
  4. Latin America
  5. Middle East & Africa
North America Chronic Kidney Disease Drugs Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Drug Class
  1. SGLT2 Inhibitors
  2. ACE Inhibitors
  3. Angiotensin II Receptor Blockers (ARBs)
  4. Direct Renin Inhibitors
  5. Mineralocorticoid Receptor Antagonists (MRAs)
  6. Endothelin Receptor Antagonists (ERAs)
  7. Immunosuppressants
  8. Corticosteroids
  9. Complement inhibitors
  10. Others
2. Market Analysis, Insights and Forecast – By Stage
  1. Stage 1
  2. Stage 2
  3. Stage 3a
  4. Stage 3b
  5. Stage 4
  6. Stage 5 (Non-Dialysis)
  7. Others
3. Market Analysis, Insights and Forecast – By Disease Indication
  1. Diabetic Kidney Disease (DKD)
  2. Hypertensive Nephropathy / Nephrosclerosis
  3. Glomerular Diseases
  4. Polycystic Kidney Disease (PKD)
  5. Chronic Tubulointerstitial Nephritis
  6. Obstructive Uropathy–related CKD
  7. Systemic Autoimmune–associated CKD
  8. Infectious/Inflammatory–associated CKD
  9. Congenital/Structural Kidney Disorders (non-PKD)
  10. Others
4. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
5. Market Analysis, Insights and Forecast – By Age Group
  1. Pediatrics
  2. Adults
6. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Drug Stores & Retail Pharmacies
  3. Online Pharmacies
7. Market Analysis, Insights and Forecast – By Country
  1. U.S.
  2. Canada
Europe Chronic Kidney Disease Drugs Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Drug Class
  1. SGLT2 Inhibitors
  2. ACE Inhibitors
  3. Angiotensin II Receptor Blockers (ARBs)
  4. Direct Renin Inhibitors
  5. Mineralocorticoid Receptor Antagonists (MRAs)
  6. Endothelin Receptor Antagonists (ERAs)
  7. Immunosuppressants
  8. Corticosteroids
  9. Complement inhibitors
  10. Others
2. Market Analysis, Insights and Forecast – By Stage
  1. Stage 1
  2. Stage 2
  3. Stage 3a
  4. Stage 3b
  5. Stage 4
  6. Stage 5 (Non-Dialysis)
  7. Others
3. Market Analysis, Insights and Forecast – By Disease Indication
  1. Diabetic Kidney Disease (DKD)
  2. Hypertensive Nephropathy / Nephrosclerosis
  3. Glomerular Diseases
  4. Polycystic Kidney Disease (PKD)
  5. Chronic Tubulointerstitial Nephritis
  6. Obstructive Uropathy–related CKD
  7. Systemic Autoimmune–associated CKD
  8. Infectious/Inflammatory–associated CKD
  9. Congenital/Structural Kidney Disorders (non-PKD)
  10. Others
4. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
5. Market Analysis, Insights and Forecast – By Age Group
  1. Pediatrics
  2. Adults
6. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Drug Stores & Retail Pharmacies
  3. Online Pharmacies
7. Market Analysis, Insights and Forecast – By Country/ Sub-Region
  1. U.K.
  2. Germany
  3. France
  4. Italy
  5. Spain
  6. Scandinavia
  7. Rest of Europe
Asia Pacific Chronic Kidney Disease Drugs Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Drug Class
  1. SGLT2 Inhibitors
  2. ACE Inhibitors
  3. Angiotensin II Receptor Blockers (ARBs)
  4. Direct Renin Inhibitors
  5. Mineralocorticoid Receptor Antagonists (MRAs)
  6. Endothelin Receptor Antagonists (ERAs)
  7. Immunosuppressants
  8. Corticosteroids
  9. Complement inhibitors
  10. Others
2. Market Analysis, Insights and Forecast – By Stage
  1. Stage 1
  2. Stage 2
  3. Stage 3a
  4. Stage 3b
  5. Stage 4
  6. Stage 5 (Non-Dialysis)
  7. Others
3. Market Analysis, Insights and Forecast – By Disease Indication
  1. Diabetic Kidney Disease (DKD)
  2. Hypertensive Nephropathy / Nephrosclerosis
  3. Glomerular Diseases
  4. Polycystic Kidney Disease (PKD)
  5. Chronic Tubulointerstitial Nephritis
  6. Obstructive Uropathy–related CKD
  7. Systemic Autoimmune–associated CKD
  8. Infectious/Inflammatory–associated CKD
  9. Congenital/Structural Kidney Disorders (non-PKD)
  10. Others
4. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
5. Market Analysis, Insights and Forecast – By Age Group
  1. Pediatrics
  2. Adults
6. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Drug Stores & Retail Pharmacies
  3. Online Pharmacies
7. Market Analysis, Insights and Forecast – By Country/ Sub-Region
  1. China
  2. Japan
  3. India
  4. Australia
  5. Southeast Asia
  6. Rest of Asia Pacific
Latin America Chronic Kidney Disease Drugs Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Drug Class
  1. SGLT2 Inhibitors
  2. ACE Inhibitors
  3. Angiotensin II Receptor Blockers (ARBs)
  4. Direct Renin Inhibitors
  5. Mineralocorticoid Receptor Antagonists (MRAs)
  6. Endothelin Receptor Antagonists (ERAs)
  7. Immunosuppressants
  8. Corticosteroids
  9. Complement inhibitors
  10. Others
2. Market Analysis, Insights and Forecast – By Stage
  1. Stage 1
  2. Stage 2
  3. Stage 3a
  4. Stage 3b
  5. Stage 4
  6. Stage 5 (Non-Dialysis)
  7. Others
3. Market Analysis, Insights and Forecast – By Disease Indication
  1. Diabetic Kidney Disease (DKD)
  2. Hypertensive Nephropathy / Nephrosclerosis
  3. Glomerular Diseases
  4. Polycystic Kidney Disease (PKD)
  5. Chronic Tubulointerstitial Nephritis
  6. Obstructive Uropathy–related CKD
  7. Systemic Autoimmune–associated CKD
  8. Infectious/Inflammatory–associated CKD
  9. Congenital/Structural Kidney Disorders (non-PKD)
  10. Others
4. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
5. Market Analysis, Insights and Forecast – By Age Group
  1. Pediatrics
  2. Adults
6. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Drug Stores & Retail Pharmacies
  3. Online Pharmacies
7. Market Analysis, Insights and Forecast – By Country/ Sub-Region
  1. Brazil
  2. Mexico
  3. Rest of Latin America
Middle East & Africa Chronic Kidney Disease Drugs Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Drug Class
  1. SGLT2 Inhibitors
  2. ACE Inhibitors
  3. Angiotensin II Receptor Blockers (ARBs)
  4. Direct Renin Inhibitors
  5. Mineralocorticoid Receptor Antagonists (MRAs)
  6. Endothelin Receptor Antagonists (ERAs)
  7. Immunosuppressants
  8. Corticosteroids
  9. Complement inhibitors
  10. Others
2. Market Analysis, Insights and Forecast – By Stage
  1. Stage 1
  2. Stage 2
  3. Stage 3a
  4. Stage 3b
  5. Stage 4
  6. Stage 5 (Non-Dialysis)
  7. Others
3. Market Analysis, Insights and Forecast – By Disease Indication
  1. Diabetic Kidney Disease (DKD)
  2. Hypertensive Nephropathy / Nephrosclerosis
  3. Glomerular Diseases
  4. Polycystic Kidney Disease (PKD)
  5. Chronic Tubulointerstitial Nephritis
  6. Obstructive Uropathy–related CKD
  7. Systemic Autoimmune–associated CKD
  8. Infectious/Inflammatory–associated CKD
  9. Congenital/Structural Kidney Disorders (non-PKD)
  10. Others
4. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
5. Market Analysis, Insights and Forecast – By Age Group
  1. Pediatrics
  2. Adults
6. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Drug Stores & Retail Pharmacies
  3. Online Pharmacies
7. Market Analysis, Insights and Forecast – By Country/ Sub-Region
  1. GCC
  2. South Africa
  3. Rest of the Middle East & Africa
Competitive Analysis
1. Global Market Share Analysis (2025)
2. Company Profiles (Overview, Products & Services, SWOT analysis, Recent developments, strategies, financials (based on availability)
  1. AstraZeneca
  2. Bayer AG
  3. Boehringer Ingelheim Pharmaceuticals, Inc.
  4. Eli Lilly and Company
  5. Novartis AG
  6. Calliditas Therapeutics AB
  7. Otsuka Pharmaceuticals Inc.
  8. GSK plc
  9. Amgen Inc.
  10. Sanofi

Read Less

List of Figures

Figure 1: Global Chronic Kidney Disease Drugs Market Revenue Breakdown (USD Billion, %) by Region, 2025 & 2034

Figure 2: Global Chronic Kidney Disease Drugs Market Value Share (%), By Drug Class, 2025 & 2034

Figure 3: Global Chronic Kidney Disease Drugs Market Value Share (%), By Stage, 2025 & 2034

Figure 4: Global Chronic Kidney Disease Drugs Market Value Share (%), By Disease Indication, 2025 & 2034

Figure 5: Global Chronic Kidney Disease Drugs Market Value Share (%), By Route of Administration, 2025 & 2034

Figure 6: Global Chronic Kidney Disease Drugs Market Value Share (%), By Age Group, 2025 & 2034

Figure 7: Global Chronic Kidney Disease Drugs Market Value Share (%), By Distribution Channel, 2025 & 2034

Figure 8: Global Chronic Kidney Disease Drugs Market Value Share (%), by Region, 2025 & 2034

Figure 9: North America Chronic Kidney Disease Drugs Market Value (USD Billion), By Drug Class, 2025 & 2034

Figure 10: North America Chronic Kidney Disease Drugs Market Value Share (%), By Drug Class, 2025

Figure 11: North America Chronic Kidney Disease Drugs Market Value (USD Billion), By Stage, 2025 & 2034

Figure 12: North America Chronic Kidney Disease Drugs Market Value Share (%), By Stage, 2025

Figure 13: North America Chronic Kidney Disease Drugs Market Value (USD Billion), By Disease Indication, 2025 & 2034

Figure 14: North America Chronic Kidney Disease Drugs Market Value Share (%), By Disease Indication, 2025

Figure 15: North America Chronic Kidney Disease Drugs Market Value (USD Billion), By Route of Administration, 2025 & 2034

Figure 16: North America Chronic Kidney Disease Drugs Market Value Share (%), By Route of Administration, 2025

Figure 17: North America Chronic Kidney Disease Drugs Market Value (USD Billion), By Age Group, 2025 & 2034

Figure 18: North America Chronic Kidney Disease Drugs Market Value Share (%), By Age Group, 2025

Figure 19: North America Chronic Kidney Disease Drugs Market Value (USD Billion), By Distribution Channel, 2025 & 2034

Figure 20: North America Chronic Kidney Disease Drugs Market Value Share (%), By Distribution Channel, 2025

Figure 21: North America Chronic Kidney Disease Drugs Market Value (USD Billion), by Country, 2025 & 2034

Figure 22: North America Chronic Kidney Disease Drugs Market Value Share (%), by Country, 2025

Figure 23: Europe Chronic Kidney Disease Drugs Market Value (USD Billion), By Drug Class, 2025 & 2034

Figure 24: Europe Chronic Kidney Disease Drugs Market Value Share (%), By Drug Class, 2025

Figure 25: Europe Chronic Kidney Disease Drugs Market Value (USD Billion), By Stage, 2025 & 2034

Figure 26: Europe Chronic Kidney Disease Drugs Market Value Share (%), By Stage, 2025

Figure 27: Europe Chronic Kidney Disease Drugs Market Value (USD Billion), By Disease Indication, 2025 & 2034

Figure 28: Europe Chronic Kidney Disease Drugs Market Value Share (%), By Disease Indication, 2025

Figure 29: Europe Chronic Kidney Disease Drugs Market Value (USD Billion), By Route of Administration, 2025 & 2034

Figure 30: Europe Chronic Kidney Disease Drugs Market Value Share (%), By Route of Administration, 2025

Figure 31: Europe Chronic Kidney Disease Drugs Market Value (USD Billion), By Age Group, 2025 & 2034

Figure 32: Europe Chronic Kidney Disease Drugs Market Value Share (%), By Age Group, 2025

Figure 33: Europe Chronic Kidney Disease Drugs Market Value (USD Billion), By Distribution Channel, 2025 & 2034

Figure 34: Europe Chronic Kidney Disease Drugs Market Value Share (%), By Distribution Channel, 2025

Figure 35: Europe Chronic Kidney Disease Drugs Market Value (USD Billion), by Country/ Sub-region, 2025 & 2034

Figure 36: Europe Chronic Kidney Disease Drugs Market Value Share (%), by Country/ Sub-region, 2025

Figure 37: Asia Pacific Chronic Kidney Disease Drugs Market Value (USD Billion), By Drug Class, 2025 & 2034

Figure 38: Asia Pacific Chronic Kidney Disease Drugs Market Value Share (%), By Drug Class, 2025

Figure 39: Asia Pacific Chronic Kidney Disease Drugs Market Value (USD Billion), By Stage, 2025 & 2034

Figure 40: Asia Pacific Chronic Kidney Disease Drugs Market Value Share (%), By Stage, 2025

Figure 41: Asia Pacific Chronic Kidney Disease Drugs Market Value (USD Billion), By Disease Indication, 2025 & 2034

Figure 42: Asia Pacific Chronic Kidney Disease Drugs Market Value Share (%), By Disease Indication, 2025

Figure 43: Asia Pacific Chronic Kidney Disease Drugs Market Value (USD Billion), By Route of Administration, 2025 & 2034

Figure 44: Asia Pacific Chronic Kidney Disease Drugs Market Value Share (%), By Route of Administration, 2025

Figure 45: Asia Pacific Chronic Kidney Disease Drugs Market Value (USD Billion), By Age Group, 2025 & 2034

Figure 46: Asia Pacific Chronic Kidney Disease Drugs Market Value Share (%), By Age Group, 2025

Figure 47: Asia Pacific Chronic Kidney Disease Drugs Market Value (USD Billion), By Distribution Channel, 2025 & 2034

Figure 48: Asia Pacific Chronic Kidney Disease Drugs Market Value Share (%), By Distribution Channel, 2025

Figure 49: Asia Pacific Chronic Kidney Disease Drugs Market Value (USD Billion), by Country/ Sub-region, 2025 & 2034

Figure 50: Asia Pacific Chronic Kidney Disease Drugs Market Value Share (%), by Country/ Sub-region, 2025

Figure 51: Latin America Chronic Kidney Disease Drugs Market Value (USD Billion), By Drug Class, 2025 & 2034

Figure 52: Latin America Chronic Kidney Disease Drugs Market Value Share (%), By Drug Class, 2025

Figure 53: Latin America Chronic Kidney Disease Drugs Market Value (USD Billion), By Stage, 2025 & 2034

Figure 54: Latin America Chronic Kidney Disease Drugs Market Value Share (%), By Stage, 2025

Figure 55: Latin America Chronic Kidney Disease Drugs Market Value (USD Billion), By Disease Indication, 2025 & 2034

Figure 56: Latin America Chronic Kidney Disease Drugs Market Value Share (%), By Disease Indication, 2025

Figure 57: Latin America Chronic Kidney Disease Drugs Market Value (USD Billion), By Route of Administration, 2025 & 2034

Figure 58: Latin America Chronic Kidney Disease Drugs Market Value Share (%), By Route of Administration, 2025

Figure 59: Latin America Chronic Kidney Disease Drugs Market Value (USD Billion), By Age Group, 2025 & 2034

Figure 60: Latin America Chronic Kidney Disease Drugs Market Value Share (%), By Age Group, 2025

Figure 61: Latin America Chronic Kidney Disease Drugs Market Value (USD Billion), By Distribution Channel, 2025 & 2034

Figure 62: Latin America Chronic Kidney Disease Drugs Market Value Share (%), By Distribution Channel, 2025

Figure 63: Latin America Chronic Kidney Disease Drugs Market Value (USD Billion), by Country/ Sub-region, 2025 & 2034

Figure 64: Latin America Chronic Kidney Disease Drugs Market Value Share (%), by Country/ Sub-region, 2025

Figure 65: Middle East & Africa Chronic Kidney Disease Drugs Market Value (USD Billion), By Drug Class, 2025 & 2034

Figure 66: Middle East & Africa Chronic Kidney Disease Drugs Market Value Share (%), By Drug Class, 2025

Figure 67: Middle East & Africa Chronic Kidney Disease Drugs Market Value (USD Billion), By Stage, 2025 & 2034

Figure 68: Middle East & Africa Chronic Kidney Disease Drugs Market Value Share (%), By Stage, 2025

Figure 69: Middle East & Africa Chronic Kidney Disease Drugs Market Value (USD Billion), By Disease Indication, 2025 & 2034

Figure 70: Middle East & Africa Chronic Kidney Disease Drugs Market Value Share (%), By Disease Indication, 2025

Figure 71: Middle East & Africa Chronic Kidney Disease Drugs Market Value (USD Billion), By Route of Administration, 2025 & 2034

Figure 72: Middle East & Africa Chronic Kidney Disease Drugs Market Value Share (%), By Route of Administration, 2025

Figure 73: Middle East & Africa Chronic Kidney Disease Drugs Market Value (USD Billion), By Age Group, 2025 & 2034

Figure 74: Middle East & Africa Chronic Kidney Disease Drugs Market Value Share (%), By Age Group, 2025

Figure 75: Middle East & Africa Chronic Kidney Disease Drugs Market Value (USD Billion), By Distribution Channel, 2025 & 2034

Figure 76: Middle East & Africa Chronic Kidney Disease Drugs Market Value Share (%), By Distribution Channel, 2025

Figure 77: Middle East & Africa Chronic Kidney Disease Drugs Market Value (USD Billion), by Country/ Sub-region, 2025 & 2034

Figure 78: Middle East & Africa Chronic Kidney Disease Drugs Market Value Share (%), by Country/ Sub-region, 2025

Figure 79: Global Chronic Kidney Disease Drugs Market Share (%), by Company, 2025

List of Tables

Table 1: Global Chronic Kidney Disease Drugs Market Revenue (USD Billion) Forecast, By Drug Class, 2021-2034

Table 2: Global Chronic Kidney Disease Drugs Market Revenue (USD Billion) Forecast, By Stage, 2021-2034

Table 3: Global Chronic Kidney Disease Drugs Market Revenue (USD Billion) Forecast, By Disease Indication, 2021-2034

Table 4: Global Chronic Kidney Disease Drugs Market Revenue (USD Billion) Forecast, By Route of Administration, 2021-2034

Table 5: Global Chronic Kidney Disease Drugs Market Revenue (USD Billion) Forecast, By Age Group, 2021-2034

Table 6: Global Chronic Kidney Disease Drugs Market Revenue (USD Billion) Forecast, By Distribution Channel, 2021-2034

Table 7: Global Chronic Kidney Disease Drugs Market Revenue (USD Billion) Forecast, by Region, 2021-2034

Table 8: North America Chronic Kidney Disease Drugs Market Revenue (USD Billion) Forecast, By Drug Class, 2021-2034

Table 9: North America Chronic Kidney Disease Drugs Market Revenue (USD Billion) Forecast, By Stage, 2021-2034

Table 10: North America Chronic Kidney Disease Drugs Market Revenue (USD Billion) Forecast, By Disease Indication, 2021-2034

Table 11: North America Chronic Kidney Disease Drugs Market Revenue (USD Billion) Forecast, By Route of Administration, 2021-2034

Table 12: North America Chronic Kidney Disease Drugs Market Revenue (USD Billion) Forecast, By Age Group, 2021-2034

Table 13: North America Chronic Kidney Disease Drugs Market Revenue (USD Billion) Forecast, By Distribution Channel, 2021-2034

Table 14: North America Chronic Kidney Disease Drugs Market Revenue (USD Billion) Forecast, by Country, 2021-2034

Table 15: Europe Chronic Kidney Disease Drugs Market Revenue (USD Billion) Forecast, By Drug Class, 2021-2034

Table 16: Europe Chronic Kidney Disease Drugs Market Revenue (USD Billion) Forecast, By Stage, 2021-2034

Table 17: Europe Chronic Kidney Disease Drugs Market Revenue (USD Billion) Forecast, By Disease Indication, 2021-2034

Table 18: Europe Chronic Kidney Disease Drugs Market Revenue (USD Billion) Forecast, By Route of Administration, 2021-2034

Table 19: Europe Chronic Kidney Disease Drugs Market Revenue (USD Billion) Forecast, By Age Group, 2021-2034

Table 20: Europe Chronic Kidney Disease Drugs Market Revenue (USD Billion) Forecast, By Distribution Channel, 2021-2034

Table 21: Europe Chronic Kidney Disease Drugs Market Revenue (USD Billion) Forecast, by Country/ Sub-region, 2021-2034

Table 22: Asia Pacific Chronic Kidney Disease Drugs Market Revenue (USD Billion) Forecast, By Drug Class, 2021-2034

Table 23: Asia Pacific Chronic Kidney Disease Drugs Market Revenue (USD Billion) Forecast, By Stage, 2021-2034

Table 24: Asia Pacific Chronic Kidney Disease Drugs Market Revenue (USD Billion) Forecast, By Disease Indication, 2021-2034

Table 25: Asia Pacific Chronic Kidney Disease Drugs Market Revenue (USD Billion) Forecast, By Route of Administration, 2021-2034

Table 26: Asia Pacific Chronic Kidney Disease Drugs Market Revenue (USD Billion) Forecast, By Age Group, 2021-2034

Table 27: Asia Pacific Chronic Kidney Disease Drugs Market Revenue (USD Billion) Forecast, By Distribution Channel, 2021-2034

Table 28: Asia Pacific Chronic Kidney Disease Drugs Market Revenue (USD Billion) Forecast, by Country/ Sub-region, 2021-2034

Table 29: Latin America Chronic Kidney Disease Drugs Market Revenue (USD Billion) Forecast, By Drug Class, 2021-2034

Table 30: Latin America Chronic Kidney Disease Drugs Market Revenue (USD Billion) Forecast, By Stage, 2021-2034

Table 31: Latin America Chronic Kidney Disease Drugs Market Revenue (USD Billion) Forecast, By Disease Indication, 2021-2034

Table 32: Latin America Chronic Kidney Disease Drugs Market Revenue (USD Billion) Forecast, By Route of Administration, 2021-2034

Table 33: Latin America Chronic Kidney Disease Drugs Market Revenue (USD Billion) Forecast, By Age Group, 2021-2034

Table 34: Latin America Chronic Kidney Disease Drugs Market Revenue (USD Billion) Forecast, By Distribution Channel, 2021-2034

Table 35: Latin America Chronic Kidney Disease Drugs Market Revenue (USD Billion) Forecast, by Country/ Sub-region, 2021-2034

Table 36: Middle East & Africa Chronic Kidney Disease Drugs Market Revenue (USD Billion) Forecast, By Drug Class, 2021-2034

Table 37: Middle East & Africa Chronic Kidney Disease Drugs Market Revenue (USD Billion) Forecast, By Stage, 2021-2034

Table 38: Middle East & Africa Chronic Kidney Disease Drugs Market Revenue (USD Billion) Forecast, By Disease Indication, 2021-2034

Table 39: Middle East & Africa Chronic Kidney Disease Drugs Market Revenue (USD Billion) Forecast, By Route of Administration, 2021-2034

Table 40: Middle East & Africa Chronic Kidney Disease Drugs Market Revenue (USD Billion) Forecast, By Age Group, 2021-2034

Table 41: Middle East & Africa Chronic Kidney Disease Drugs Market Revenue (USD Billion) Forecast, By Distribution Channel, 2021-2034

Table 42: Middle East & Africa Chronic Kidney Disease Drugs Market Revenue (USD Billion) Forecast, by Country/ Sub-region, 2021-2034

STUDY PERIOD: 2021-2034
BASE YEAR: 2025
HISTORICAL DATA: 2021-2024
NO OF PAGES: 204

Buy Now

Download Free Sample

Security Code

Get 20% Free Customization

Expand Regional and Country Coverage, Segments Analysis, Company Profiles, Competitive Benchmarking, and End-user Insights.

Growth Advisory Services

Clients

Related Reports

Get In Touch With Us

US +1 833 909 2966 ( Toll Free )

UK +44 808 502 0280 ( Toll Free )

(APAC) +91 744 740 1245
sales@fortunebusinessinsights.com